Recent And Upcoming FDA Advisory Committee Meetings
Executive Summary
Recent and upcoming US FDA advisory committee meetings and a summary of topics covered.
You may also be interested in...
Amarin’s Vascepa Positioned For Broad CV Risk Reduction Claim Following US FDA Panel Nod
Despite FDA's concerns, advisory committee unanimously endorses Vascepa's labeling expansion, with 10 of 16 members also favoring approval for secondary as well as primary prevention even as several voiced misgivings about efficacy in the REDUCE-IT trial's lower risk cohort.
Empagliflozin Likely Needs Another Trial After Rebuke By US FDA Panel
Expanded indication for type 1 diabetes seems out of reach for the moment, but if Boehringer conducts a larger and lengthier trial, it could eventually persuade members of the Endocrinologic and Metabolic Drugs Advisory Committee who voted 14-2 against supplemental approval of empagliflozin for the proposed 2.5mg dose.
Vascepa Advisory Committee Is Latest Outpost In Product's Remarkable Regulatory Journey
The last time representatives from Amarin and US FDA formally met in public, it was in court.